Pheochromocytoma clinical trials at UCSF
3 in progress, 1 open to eligible people
Project: Every Child for Younger Patients With Cancer
open to eligible people ages up to 25 years
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Oakland, California and other locations
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
Sorry, in progress, not accepting new patients
This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size.
Oakland, California and other locations
Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
Sorry, not accepting new patients
This is a compassionate use protocol to allow palliative therapy for patients with malignant pheochromocytoma and paragangliomas.
San Francisco, California
Our lead scientists for Pheochromocytoma research studies include Jennifer G. Michlitsch Arun A. Rangaswami.
Last updated: